Tinidazole in the treatment of bacterial vaginosis

Nicola R Armstrong, Janet D Wilson, Nicola R Armstrong, Janet D Wilson

Abstract

Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women of childbearing age. Oral metronidazole has long been established as an effective therapy in the treatment of BV. However, adverse effects due to metronidazole are frequent and this may lead to problems with adherence to a 7-day course of treatment and subsequently result in treatment failure. Oral tinidazole has been used to treat bacterial vaginosis for over 25 years but in a number of different dosage regimens. Placebo controlled trials have consistently shown increases in cure rate with tinidazole. Longer courses of treatment (eg, 1 g daily for 5 days) appear to be more effective than a 2 g oral single dose. Comparative studies suggest that oral tinidazole is equivalent to oral metronidazole, intravaginal clindamycin cream, and intravaginal metronidazole tablets, in efficacy in treating BV. However, tinidazole has a more favorable side effect profile than oral metronidazole notably with better gastrointestinal tolerability and less metallic taste. Bacterial vaginosis is associated with high rates of recurrence and appropriate management of such recurrences can prove difficult. Recurrent BV has been linked with persistence of Gardnerella vaginalis after treatment; however the clinical implications of the possible greater activity of tinidazole against G. vaginalis are not yet clear. Repeated courses of oral metronidazole may be poorly tolerated and an alternative but equally effective treatment that is better tolerated may be preferable. In comparison to oral metronidazole, cost is clearly an issue as oral metronidazole is considerably cheaper and available in generic form. However where avoidance of oral metronidazole is necessary because of side effects, oral tinidazole is a cost-effective alternative.

Keywords: Gardnerella vaginalis; bacterial vaginosis; metronidazole; tinidazole.

References

    1. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80:8–11.
    1. Ferris MJ, Masztal A, Aldridge KE, Fortenberry D, Fidel PL, Jr, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis. 2004;4:5.
    1. Fredricks D, Fiedler BS, Marazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Eng J Med. 2005;353:1899–1911.
    1. Amsel R, Totten PA, Spiegal CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22.
    1. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301.
    1. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Hussein P. Bacterial vaginosis as a risk factor for preterm delivery: A meta-analysis. Am J Obstet Gynecol. 2003;189:139–147.
    1. Soper DE. Bacterial vaginosis and postoperative infections. Am J Obstet Gynaecol. 1993;169:467–469.
    1. Ness RB, Kip KE, Hillier SL, Soper DE, Stamm CA, Sweet RL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005;162:585–590.
    1. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances in vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12:1699–1706.
    1. Martin H, Nyange PM, Richardson BA, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180:1863–1868.
    1. Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Diseases. 1995;20(Suppl 1):s72–s79.
    1. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999;28(suppl 1):s57–s65.
    1. Brandt M, Abels C, May T, Lohmann K, Schmidts-Winkler I, Hoyme UB. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur J Obstet Gynecol Reprod Biol. 2008;141:158–162.
    1. Miller MW, Howes HL, English AR. Tinidazole, a potent new antiprotazoal agent. Antimicrob Agents Chemother. 1969;1:257–260.
    1. Fung HB, Doan T. Tinidazole: a nitroimidazole antiprotazoal agent. Clin Ther. 2005;27:1859–1884.
    1. Mattila J, Mannisto PT, Mantyla R, Nykanen S, Lamminsivu U. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother. 1983;23:721–725.
    1. Mannisto P, Karhunen M, Mattila J, et al. Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration. Infection. 1984;12:197–201.
    1. Nord CE, Kager L. Tinidazole-microbiology, pharmacology and efficacy in anaerobic infections. Infection. 1983;11:54–60.
    1. Carmona O, Silva H, Acosta H. Vaginitis due to Gardenerella vaginalis: treatment with tinidazole. Curr Ther Res. 1983;22:898–904.
    1. Mohanty KC, Deighton R. Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis. J Antimicrob Chemother. 1987;19:393–399.
    1. Austin MN, Meyn LA, Hillier SL. Susceptibility of vaginal bacteria to metronidazole and tinidazole. Anaerobe. 2006;12:227–230.
    1. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother. 1987;31:249–252.
    1. Larsson PG. Treatment of bacterial vaginosis. Int J STD AIDS. 1992;3:239–247.
    1. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER) Guidance for industry: bacterial vaginosis – developing antimicrobial drugs for treatment. Draft guidance. Jul, 1998. Available at: .
    1. Thomas KK, Sanchez S, Garcia PJ, et al. Why do different criteria for ‘cure’ yield different conclusions in comparing two treatments for bacterial vaginosis? Sex Transm Dis. 2005;32:526–530.
    1. Livengood CH, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomised controlled trial. Obstet Gynaecol. 2007;110:302–309.
    1. Paavonen J, Vesterinen E, Purola E, et al. Single dose of tinidazole in the treatment of vaginal discharge. Scand J Urol Nephrol Suppl. 1984;86:237–240.
    1. Piot P, Van Dyck E, Godts P, Vanderheyden J. A placebo-controlled, double-blind comparison of tinidazole and triple sulfonamide cream for the treatment of nonspecific vaginitis. Am J Obstet Gynaecol. 1983;147:85–89.
    1. van der Meijden WI. Treatment of nonspecific vaginitis with a single dose of tinidazole. Scand J Infect Dis Suppl. 1983;40:85–89.
    1. Ekgren J, Norling BK, Degre M, Midtvedt T. Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis. Gynaecol Obstet Invest. 1988;26:313–317.
    1. Sanz-Sanz F, Hernanz AD, Sancher EA, Alvarez CG, Muelas M, Rodriguez-Noriega A. Controlled comparative study of metronidazole (Flagyl) versus tinidazole (Tricolan) in the treatment of nonspecific vaginitis (vaginitis due to Gardnerella vaginalis) Rev Gynaecol Obstet. 1985;44:717–720.
    1. Buranawarodomkul P, Chandeying V, Sutthijumroon S. Seven day metronidazole versus single dose tinidazole as therapy for nonspecific vaginitis. J Med Assoc Thai. 1990;73:283–287.
    1. Sanz-Sanz F, Arreaza L, Vidriales I, Miranda P, Grande J, Valle R. Concerning the different therapeutic options for bacterial vaginosis. Progresso Obstet Ginecol. 1996;39:669–674.
    1. Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomised, investigator-blinded controlled trial. Eur J Obstet Gynaecol Reprod Biol. 2003;109:67–71.
    1. Milani M, Baldoni A, Guerro B, Spinillo A. The “talent” multicenter trial: efficacy of tinidazole, metronidazole, and tinidazole + acidic gel in the treatment of B.vaginosis; Abstracts of the 86th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology; Venice, Italy. November 2003.
    1. Schindler EM, Thamm H, Ansmann EB, Sarnow E, Schindler AE. Treatment of bacterial vaginitis. Multicenter, randomised, open study with tinidazole in comparison with metronidazole. Fortschr Med. 1991;109(5):138–140.
    1. Nailor MD, Sobel JD. Tindazole for bacterial vaginosis. Expert Opin Investig Drugs. 2007;16:743–751.
    1. CDC Sexually transmitted diseases treatment guidelines MMWR 2006 RR-11. Available from .
    1. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194:828–836.
    1. Meltzer MC, Desmond RA, Schwebke JR. Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis. 2008;35:611–613.
    1. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med. 2008;149:20–28.
    1. United Kingdom National Guideline for the management of bacterial vaginosis 2006. Available from
    1. Australasian College of Sexual Health Physicians: Clinical Guidelines for the management of sexually transmissible infections among priority populations 2004. Available from
    1. Sherrard J. European Guideline for the management of vaginal discharge. Int J STD AIDS. 2001;12(suppl 3):73–77.
    1. World Health Organisation Guidelines for the Management of Sexually Transmitted Infections. 2003.
    1. Ottawa, ON: Public Health Agency of Canada; Canadian Guidelines on Sexually Transmitted Infections. [Revised January 2008] Available from .
    1. Apte VV, Packard RS. Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study. Drugs. 1978;15(Suppl 1):43–48.
    1. Bashki JS, Ghiara JM, Nanivadekar AS. How does tinidazole compare with metronidazole? A summary report of Indian trials in amoebiasis and giardiasis. Drugs. 1978;15(suppl 1):33–42.
    1. British National Formulary (BNF) 57. March 2009. Available from

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi